430 related articles for article (PubMed ID: 33713359)
1. Ribociclib Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Analysis of Neutrophils in Cancer Patients.
Lu Y; Yang S; Ho YY; Ji Y
J Clin Pharmacol; 2021 Aug; 61(8):1054-1068. PubMed ID: 33713359
[TBL] [Abstract][Full Text] [Related]
2. Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast Cancer.
Ji Y; Schiller H; Yang S; Quinlan M; Darstein C; Huth F; Winter S; Chakraborty A
Clin Pharmacokinet; 2024 Feb; 63(2):155-170. PubMed ID: 38244190
[TBL] [Abstract][Full Text] [Related]
3. Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.
Rascon K; Flajc G; De Angelis C; Liu X; Trivedi MV; Ekinci E
Ann Pharmacother; 2019 May; 53(5):501-509. PubMed ID: 30522347
[TBL] [Abstract][Full Text] [Related]
4. FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.
Shah A; Bloomquist E; Tang S; Fu W; Bi Y; Liu Q; Yu J; Zhao P; Palmby TR; Goldberg KB; Chang CJG; Patel P; Alebachew E; Tilley A; Pierce WF; Ibrahim A; Blumenthal GM; Sridhara R; Beaver JA; Pazdur R
Clin Cancer Res; 2018 Jul; 24(13):2999-3004. PubMed ID: 29437768
[TBL] [Abstract][Full Text] [Related]
5. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
Tripathy D; Im SA; Colleoni M; Franke F; Bardia A; Harbeck N; Hurvitz SA; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva Vazquez R; Jung KH; Babu KG; Wheatley-Price P; De Laurentiis M; Im YH; Kuemmel S; El-Saghir N; Liu MC; Carlson G; Hughes G; Diaz-Padilla I; Germa C; Hirawat S; Lu YS
Lancet Oncol; 2018 Jul; 19(7):904-915. PubMed ID: 29804902
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of Ribociclib in Subjects With Hepatic Impairment.
Samant TS; Yang S; Miller M; Ji Y
J Clin Pharmacol; 2021 Aug; 61(8):1001-1009. PubMed ID: 33555033
[TBL] [Abstract][Full Text] [Related]
7. Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial.
Hortobagyi GN
Breast Cancer Res; 2018 Oct; 20(1):123. PubMed ID: 30340505
[TBL] [Abstract][Full Text] [Related]
8. Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
López-Tarruella S; Jerez Y; Márquez-Rodas I; Echavarria I; Martin M
Future Oncol; 2017 Oct; 13(24):2137-2149. PubMed ID: 28758424
[TBL] [Abstract][Full Text] [Related]
9. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Hortobagyi GN; Stemmer SM; Burris HA; Yap YS; Sonke GS; Paluch-Shimon S; Campone M; Petrakova K; Blackwell KL; Winer EP; Janni W; Verma S; Conte P; Arteaga CL; Cameron DA; Mondal S; Su F; Miller M; Elmeliegy M; Germa C; O'Shaughnessy J
Ann Oncol; 2018 Jul; 29(7):1541-1547. PubMed ID: 29718092
[TBL] [Abstract][Full Text] [Related]
10. MONALEESA clinical program: a review of ribociclib use in different clinical settings.
Yardley DA
Future Oncol; 2019 Aug; 15(23):2673-2686. PubMed ID: 31305131
[TBL] [Abstract][Full Text] [Related]
11. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
Prat A; Saura C; Pascual T; Hernando C; Muñoz M; Paré L; González Farré B; Fernández PL; Galván P; Chic N; González Farré X; Oliveira M; Gil-Gil M; Arumi M; Ferrer N; Montaño A; Izarzugaza Y; Llombart-Cussac A; Bratos R; González Santiago S; Martínez E; Hoyos S; Rojas B; Virizuela JA; Ortega V; López R; Céliz P; Ciruelos E; Villagrasa P; Gavilá J
Lancet Oncol; 2020 Jan; 21(1):33-43. PubMed ID: 31838010
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer.
Fasching PA; Decker T; Hartkopf A; Nusch A; Heinrich BJ; Kurbacher C; Fuchs R; Tesch H; Krabisch P; Huober J; Kuemmel S; Brucker S; Janni W; Schneeweiss A; Schuler M; Fehm T; Lüftner D; Quiering C; Voges C; Kreuzeder J; Reinisch M
Eur J Cancer; 2024 Feb; 198():113480. PubMed ID: 38154393
[TBL] [Abstract][Full Text] [Related]
13. Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations.
Samant TS; Dhuria S; Lu Y; Laisney M; Yang S; Grandeury A; Mueller-Zsigmondy M; Umehara K; Huth F; Miller M; Germa C; Elmeliegy M
Clin Pharmacol Ther; 2018 Aug; 104(2):374-383. PubMed ID: 29134635
[TBL] [Abstract][Full Text] [Related]
14. Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.
O'Shaughnessy J; Petrakova K; Sonke GS; Conte P; Arteaga CL; Cameron DA; Hart LL; Villanueva C; Jakobsen E; Beck JT; Lindquist D; Souami F; Mondal S; Germa C; Hortobagyi GN
Breast Cancer Res Treat; 2018 Feb; 168(1):127-134. PubMed ID: 29164421
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study.
Yardley DA; Hart L; Favret A; Blau S; Diab S; Richards D; Sparano J; Beck JT; Richards P; Ward P; Ramaswamy B; Tsai M; Blackwell K; Pluard T; Tolaney SM; Esteva FJ; Truica CI; Alemany C; Volas-Redd G; Shtivelband M; Purkayastha D; Dalal AA; Miller M; Hortobagyi GN
Clin Breast Cancer; 2019 Aug; 19(4):268-277.e1. PubMed ID: 31160171
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer.
Curigliano G; Criscitiello C; Esposito A; Intra M; Minucci S
Expert Opin Drug Metab Toxicol; 2017 May; 13(5):575-581. PubMed ID: 28395543
[TBL] [Abstract][Full Text] [Related]
17. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.
Slamon DJ; Neven P; Chia S; Fasching PA; De Laurentiis M; Im SA; Petrakova K; Bianchi GV; Esteva FJ; Martín M; Nusch A; Sonke GS; De la Cruz-Merino L; Beck JT; Pivot X; Vidam G; Wang Y; Rodriguez Lorenc K; Miller M; Taran T; Jerusalem G
J Clin Oncol; 2018 Aug; 36(24):2465-2472. PubMed ID: 29860922
[TBL] [Abstract][Full Text] [Related]
18. Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study.
Eser K; Önder AH; Sezer E; Çil T; İnal A; Öztürk B; Erçolak V; Duman BB; Çelik H; Köşeci T; Kesen O
BMC Cancer; 2022 May; 22(1):516. PubMed ID: 35525929
[TBL] [Abstract][Full Text] [Related]
19. FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.
Gao JJ; Osgood CL; Feng Z; Bloomquist EW; Tang S; Chang CJG; Ricks TK; Hou SC; Pierce WF; Rivera DR; Pazdur R; Kluetz PG; Amiri-Kordestani L
Clin Cancer Res; 2023 Dec; 29(24):5008-5011. PubMed ID: 37594723
[TBL] [Abstract][Full Text] [Related]
20. Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study.
Fasching PA; Beck JT; Chan A; De Laurentiis M; Esteva FJ; Jerusalem G; Neven P; Pivot X; Bianchi GV; Martin M; Chandiwana D; Lanoue B; Ridolfi A; Wang Y; Rodriguez Lorenc K; Nusch A
Breast; 2020 Dec; 54():148-154. PubMed ID: 33065342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
